# Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy

> **NCT02402231** · PHASE2 · UNKNOWN · sponsor: **Caroline Nilsson** · enrollment: 23 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT02402231
- **Lead sponsor:** Caroline Nilsson
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02402231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02402231, "Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02402231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*